EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Increasing acceptance of AI ‐generated digital twins through clinical trial applications

Anna A Vidovszky iD, Charles K Fisher iD, Anton D Loukianov iD, Aaron M Smith iD, Eric W Tramel iD, Jonathan R Walsh, Jessica L Ross iD

Clinical and Translational Science · 2024-07 · 17 (7)

DOI: 10.1111/cts.13897 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 22.07.2024. Verfasst von Anna A Vidovszky und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unlearn.AI, San Francisco, California, USA. Hauptthemen laut MEDLINE: Artificial Intelligence, Clinical Trials as Topic, Precision Medicine. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Today's approach to medicine requires extensive trial and error to determine the proper treatment path for each patient. While many fields have benefited from technological breakthroughs in computer science, such as artificial intelligence (AI), the task of developing effective treatments is actually getting slower and more costly. With the increased availability of rich historical datasets from previous clinical trials and real‐world data sources, one can leverage AI models to create holistic forecasts of future health outcomes for an individual patient in the form of an AI‐generated digital twin. This could support the rapid evaluation of intervention strategies in silico and could eventually be implemented in clinical practice to make personalized medicine a reality. In this work, we focus on uses for AI‐generated digital twins of clinical trial participants and contend that the regulatory outlook for this technology within drug development makes it an ideal setting for the safe application of AI‐generated digital twins in healthcare. With continued research and growing regulatory acceptance, this path will serve to increase trust in this technology and provide momentum for the widespread adoption of AI‐generated digital twins in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceClinical Trials as TopicPrecision MedicineHumansDrug Development

Autor:innen und Institutionen

  • Unlearn.AI, San Francisco, California, USA.

ORCID-Profile: Anna A Vidovszky, Charles K Fisher, Anton D Loukianov, Aaron M Smith, Eric W Tramel, Jessica L Ross

Zitieren

APA

Vidovszky, A. A., Fisher, C. K., Loukianov, A. D., Smith, A. M., Tramel, E. W., Walsh, J. R., & Ross, J. L. (2024). Increasing acceptance of AI ‐generated digital twins through clinical trial applications. Clinical and Translational Science, 17(7). https://doi.org/10.1111/cts.13897

Vancouver

Vidovszky AA, Fisher CK, Loukianov AD, Smith AM, Tramel EW, Walsh JR, et al. Increasing acceptance of AI ‐generated digital twins through clinical trial applications. Clinical and Translational Science. 2024;17(7). doi:10.1111/cts.13897

BibTeX
@article{Vidovszky2024,
  author = {Vidovszky, Anna A and Fisher, Charles K and Loukianov, Anton D and Smith, Aaron M and Tramel, Eric W and Walsh, Jonathan R and Ross, Jessica L},
  title = {Increasing acceptance of AI ‐generated digital twins through clinical trial applications},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {7},
  doi = {10.1111/cts.13897}
}
Kostenlos starten →